gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TCRXHealthcareBiotechnology

TScan Therapeutics, Inc. Common Stock (TCRX)

$0.1774−15.52%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.18▼ 84.16% in range
Nov 4, 2025Low $0.17 · High $1.43Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

TScan Therapeutics closed at $0.18 on Nov 5, down 15.52%, within 1.7% of its 52-week closing low. Volume of 529.4K shares was 0.95× its 20-day average (close to normal).

Split-adjusted performance: -35.9% over one month, -85.3% over six months, -84.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.05M, down 65.8% from a year earlier, with a net margin of -2888.6%.

Short interest was 2.3M shares at the Oct 15 settlement, down 8.4% from the prior report (4.1% of float, 3.4 days to cover).

Market cap$12.0M67.8M shares
Revenue · quarter$1.1M−65.8% YoY
Diluted EPS$-0.23—
P/E · TTM—P/S 1.7×
Net margin-2,888.6%Gross 100.0%
Dividend yieldNone
52-week range0.17 – 1.43−87.6% from high
Volume529.4K0.95× 20-day avg
Volatility · 60d146.0%Annualised
Short % of float4.1%3.4 days to cover
Net cash$67.4MCash $100.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.0%1M −35.9%3M −77.7%6M −85.3%YTD −82.3%1Y −84.2%3Y −95.4%5Y −98.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum3
Revenue growth18
Net margin17
Value (low P/E)—
Size10

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →
Shares short2.3M−8.4% vs prior
Days to cover3.4Settled Oct 15
% of float4.1%
Short vol. 10d45.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TCRXTScan Therapeutics$0.1774−15.52%−85.3%−65.8%−2888.6%—$12.0M
SCLXScilex Holding$1.61−12.02%−80.0%−22.8%−1501.3%—$11.3MCompare
BCDABioCardia$0.8510−6.80%−21.9%———$12.9MCompare
PASGPassage Bio$3.40−3.28%−16.8%———$10.9MCompare
DYAIDyadic International$0.3520−4.01%−52.8%−0.6%−221.0%—$14.1MCompare
ATYRaTyr Pharma$5.97−3.40%−83.8%———$14.9MCompare
ABOSAcumen Pharmaceuticals$0.2102−2.82%−91.5%———$15.2MCompare
JSPRJasper Therapeutics$0.4700−8.04%−48.3%———$15.6MCompare
INTSIntensity Therapeutics$2.81−19.71%−45.0%———$9.2MCompare

News about TScan Therapeutics

All news →
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationGlobeNewswire Inc. · Jun 22, 2026▲ PositiveTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. · May 6, 2026▲ PositiveTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc. · Apr 8, 2026▲ PositiveTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03GlobeNewswire Inc. · Feb 26, 2026▲ Positive

Quick answers

What does TScan Therapeutics do?
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation.
What is TCRX's market cap?
$12.02M, based on the Nov 5 close of $0.18.
Does TScan Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TCRX is sold short?
2.3M shares, 4.1% of float, as of Oct 15, 2026.
What sector is TCRX in?
Healthcare, in the Biotechnology industry.

About TScan Therapeutics

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

HQ: Waltham, MA142 employeesListed Jul 16, 2021tscan.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology